Research validates the efficacy and accuracy of its digital solutions designed to detect early indicators of cognitive impairment

BOSTON, March 5, 2025 /PRNewswire/ — Linus Health has announced that it has hit a major milestone with over 145 peer-reviewed studies conducted and authored by leaders and staff from the company and its affiliates. Since 2019, Linus Health and its affiliates have published 72 peer-reviewed publications and delivered 75 scientific presentations at academic conferences. Linus Health is revolutionizing brain health with trusted, science-driven solutions, delivering a comprehensive, end-to-end strategy that supports early detection, intervention, and continuous care across all settings.

The majority of the published research features investigations and validations of the efficacy and accuracy of various elements and solutions within the Linus Health platform designed to promote brain health, detect early indicators of cognitive impairment, and predict the risk of Alzheimer’s disease and other forms of dementia.

To date, Linus Health has completed more than 40 clinical trials and 25 validation studies and has filed 33 patents supporting its technology, which is available in 18 languages.

“These landmark achievements reflect Linus Health’s unwavering dedication to scientific validation as we scale and enhance our offerings and capabilities,” said Linus Health Co-Founder and Chief Medical Officer Alvaro Pascual-Leone, MD, PhD. “This is a bench to bedside commitment, ensuring that we are at the forefront of advancing brain health within both life sciences and healthcare.”

A sampling of some of the most noteworthy recent studies published by Linus Health clinicians and researchers includes:

The Journal of Alzheimer’s Disease, November 2024: Detecting functional impairment with the Digital Clock and Recall. Linus Health Digital Clock and Recall (DCR™) assessment delivers a clinically meaningful evaluation of functional impairment and accurately identifies which patients require more comprehensive care, such as advanced diagnostic testing, specialist referrals, and care partner support.

Scientific Reports, September 2024: Digital speech hearing screening using a quick novel mobile hearing impairment assessment: an observational correlation study. The authors concluded that Linus Health’s digital hearing screening tool quickly, efficiently, and accurately identifies early signs of speech hearing impairment compared to lengthier audiometric tests.

Frontiers in Neurology, June  2024: Towards a lifelong personalized brain health program: empowering individuals to define, pursue, and monitor meaningful outcomes. The article describes a technology-enabled, scalable approach to guide clinical decisions and outcome evaluations about brain health that effectively incorporate patients’ treatment priorities.

Alzheimer’s & Dementia: Diagnosis, Assessment, & Disease Monitoring, February 2024: Clinical classification of memory and cognitive impairment with multimodal digital biomarkers. The article demonstrates the great utility of multimodal assessment with the DCR for identifying verbal memory impairment as confirmed by the Rey Auditory Verbal Learning Test (RAVLT).

Alzheimer’s Research & Therapy, January 2024: Digital Clock and Recall is superior to the Mini‑Mental State Examination for the detection of mild cognitive impairment and mild dementia. Results of a clinical trial show that the DCR outperforms the most commonly used paper-based assessment in detecting early mild cognitive impairment and mild dementia and with less ethnic bias.

Research Strength Matches Company Growth
Meanwhile, Linus Health continues to expand and diversify the company while raising awareness of its capabilities through awards and high-profile speaking engagements.

Acquisitions. Since 2020, Linus Health has completed four acquisitions. Most recently, it acquired Aural Analytics, a leader in clinical-grade speech analytics, and Together Senior Health, a brain health company delivering evidence-based solutions for individuals with cognitive decline due to Alzheimer’s disease and related dementias. In 2022, it acquired Kinesis Health Technologies, a leader in physical function assessment for older adults; and in 2020, it acquired Digital Cognition Technologies, a leader in digital cognitive assessment.

Awards. Linus Health has earned numerous prestigious digital health and technology awards over the years. Most recently, Linus Health was named one of Fierce Healthcare’s Fierce 15 of 2025, an annual special report highlighting innovative and creative private healthcare companies striving to change the world by changing the healthcare industry. Linus Health was also named the “Best in Class” winner in the Digital Health Hub Foundation’s Digital Health Awards 2024 in the Longevity category. The awards recognize companies that “hold the promise of transforming healthcare systems by improving access, efficiency, quality of care, patient outcomes, and addressing cost challenges,” according to its founders.

Speaking Engagements. John Showalter, MD, MSIS, chief strategy officer of Linus Health, was invited to discuss breakthroughs in the early detection of dementia at the HLTH Event 2024 in Las Vegas. Participating in the “Brainiacs” panel, Showalter explained how primary care physicians and neurologists can leverage innovative digital tools that can make early detection of mild cognitive impairment, the precursor of dementia, as routine as any other preventive screening.

In 2024, Ali Jannati, MD, PhD, director of cognitive science at Linus Health, presented the company’s latest research on concurrent identification of cognitive impairment and likely amyloid-beta status on PET using the DCR in a featured research panel at the Alzheimer’s Association International Conference (AAIC) in Philadelphia. Stina Saunders, PhD, personalized medicine lead at Linus Health, delivered an AAIC presentation focusing on the company’s electronic person-specific outcome measure tool. In addition, Linus Health scientists delivered 10 poster presentations at AAIC. More than 14,000 attendees joined the world’s largest dementia conference for its robust scientific program.

Linus Health leaders were also invited to deliver 4 unique poster presentations at the 17th annual Clinical Trials on Alzheimer’s Disease conference in Madrid, Spain. The global conference attracts over 2,000 leading experts onsite and online to discuss the latest therapeutic advances in Alzheimer’s disease.

“Our many achievements and growing industry recognition reflect an emerging consensus that the best clinical pathway to help more people prevent the progression of dementia and other forms of cognitive impairment is through promotion of brain health, prevention of disease, early detection, and evidence-based lifestyle modifications,” said Linus Health Co-Founder and CEO David Bates, PhD. “Our learnings, as well as those of our peers, will continue to inform our solution development in the coming years as we look forward to helping more patients achieve optimal outcomes and a higher quality of life.”

About Linus Health
Linus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier, and healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit www.linushealth.com or follow us on LinkedIn.

Media Contact
Tara Stultz (Amendola for Linus Health)
440-225-9595
tstultz@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/linus-health-achieves-landmark-research-recognition-across-peer-reviewed-medical-and-scientific-journals-302393368.html

SOURCE Linus Health